Navigation Links
LLS's Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
Date:9/20/2012

WHITE PLAINS, N.Y., Sept. 20, 2012 /PRNewswire/ -- Thanks to support funding from The Leukemia & Lymphoma Society (LLS), Onconova Therapeutics, Inc. has been advancing rigosertib, the lead compound under development for treating patients with high-risk myelodysplastic syndrome (MDS). 

In an announcement made this week, European commercial rights for rigosertib have been licensed to Baxter International providing significant resources to advance the program toward U.S. and European regulatory review and ultimately to MDS patients.  Rigosertib is designed to inhibit critical pathways to the growth and survival of cancer cells. 

"Advancing new therapies in areas of unmet medical need such as MDS is the bow of the ship for LLS," said LLS President and CEO John Walter. "The Baxter/Onconova agreement highlights a successful outcome for the LLS Therapy Acceleration Program (TAP)."

LLS and Onconova first announced their collaboration in June 2010. LLS has committed to providing up to $12.5 million in funding to support an ongoing multicenter, randomized, clinical trial of rigosertib versus best supportive care in adult patients with MDS who have relapsed or become resistant to azacitidine or decitabine. Onconova has announced that, to date, trial enrollment has successfully surpassed the half-way point and there are now 80 trial sites activated around the globe.  Onconova is continuing to accrue patients for the clinical trial.

This partnership marks the first phase 3, approval-track clinical trial that LLS is supporting through TAP, a bold initiative designed to bring promising therapies to patients suffering from blood cancers more quickly.  LLS is taking an active role in accelerating development of novel therapies for patients and&#
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. StemGenex to Launch Adult Stem Cell-Based Therapy to Relieve COPD Symptoms
2. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
3. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
5. New gene therapy strategy boosts levels of deficient protein in Friedreichs ataxia
6. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
7. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
8. First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
9. Gold nanoparticles could treat prostate cancer with fewer side effects than chemotherapy
10. Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis
11. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... 2013 Through science fairs, workshops, kits ... lab equipment, 25 organizations will continue their work to ... and photonics in daily life with the aid of ... located in 10 countries, are the first of two ... SPIE, the international society for optics and photonics ...
(Date:5/21/2013)... 2013 Clinverse, Inc. , ... clinical trials, announced today it has formed a ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship ... and reporting transfer of value at investigator meetings ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Emerson ... announced that Dr. Charles Signorino, the Company’s Chief Executive ... 1, 2013 after 32 years of service. As part ... Emerson’s current President, has been named as Dr. Signorino’s ... in the pharmaceutical industry, having made a significant contribution ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3
... Quark Pharmaceuticals, Inc.,a development-stage pharmaceutical company ... therapeutics, today announced the,presentation of posters ... taking place,September 16-18, 2008 in Stockholm, ... Hagar Kalinski, and Hagit Ashush, presented ...
... 17 Dendreon Corporation,(Nasdaq: DNDN ) today announced ... of Dendreon, will present a company update at the,UBS ... Monday, September,22, 2008 at 1:30 p.m. ET., A ... through the,Investor Relations section of the Dendreon website, http://www.dendreon.com ...
... China, Sept. 17 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, ... the "Company"), one of the leading plasma-based ... ("PRC"), today announced that the Company,received approval ... Administration (the,"SFDA") to commence clinical trial of ...
Cached Biology Technology:Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 2Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 3China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3
(Date:5/21/2013)... Mo. Cancers of all types become most deadly ... Once cancer has reached this stage, it becomes very ... tumors that can develop. Now, researchers at the University ... nanoparticles that target lymphoma tumor cells wherever they may ... of oncology in the MU College of Veterinary Medicine, ...
(Date:5/21/2013)... Society (ACS), the world,s largest scientific society, invites ... & Exposition, September 8-12, 2013, in Indianapolis, Ind. ... Center and at area hotels. , With more ... science,s horizons from astronomy to zoology ― ... journalists a rich assortment of spot news and ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... of plants genetically tweaked to absorb more contaminants, researchers ... wild-type counterparts. The results raised hopes that the plants ... soil. , The new research findings, published Feb. 1 ... three transgenic lines of the Indian mustard plant, Brassica ...
... of Cell Metabolism has provided insight into a key ... suggests a novel approach to the development of cholesterol-lowering ... of the most prescribed cholesterol inhibitors, according to researchers ... Cells obtain cholesterol, an important component of cell membranes, ...
... Washington Alaska Salmon Program, the world's longest-running effort to ... million from the Gordon and Betty Moore Foundation to ... program has applications for Pacific salmon all along the ... salmon runs and their management. , The grant boosts ...
Cached Biology News:Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 2Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 4Insight into natural cholesterol control suggests novel cholesterol-lowering therapy 2Alaskan puzzles, monitoring provide insight about North Pacific salmon runs 2
DTT 50 l...
...
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Biology Products: